Variations in peripheral NK cell (CD3− CD56+) bioactivities were first investigated in patients with NAFLD at different stages (slight and middle) on the basis of ultrasonic diagnosis. This evidence concerns the gene NCAM1 and metabolic dysfunction-associated steatotic liver disease.